MX370433B - Derivados de 7h-imidazo [1-5-a] pirazin-8-ona como inhibidores de la fosfodiasterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos. - Google Patents
Derivados de 7h-imidazo [1-5-a] pirazin-8-ona como inhibidores de la fosfodiasterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos.Info
- Publication number
- MX370433B MX370433B MX2015004422A MX2015004422A MX370433B MX 370433 B MX370433 B MX 370433B MX 2015004422 A MX2015004422 A MX 2015004422A MX 2015004422 A MX2015004422 A MX 2015004422A MX 370433 B MX370433 B MX 370433B
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- formula
- effective amount
- therapeutically effective
- pde9i
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se dirige a compuestos que son inhibidores de la enzima PDE9. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de la invención y un transportador farmacéuticamente aceptable. La presente invención proporciona también procesos para la preparación de los compuestos de fórmula (I). La presente invención proporciona además a un método para tratar un sujeto que padece un trastorno neurodegenerativo que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula (I). La presente invención proporciona además un método para tratar un paciente que padece un trastorno psiquiátrico que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011001692 | 2011-10-10 | ||
PCT/EP2012/069936 WO2013053690A1 (en) | 2011-10-10 | 2012-10-09 | Pde9i with imidazo pyrazinone backbone |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015004422A MX2015004422A (es) | 2015-10-15 |
MX370433B true MX370433B (es) | 2019-12-13 |
Family
ID=47019007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015004422A MX370433B (es) | 2011-10-10 | 2012-10-09 | Derivados de 7h-imidazo [1-5-a] pirazin-8-ona como inhibidores de la fosfodiasterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos. |
Country Status (15)
Country | Link |
---|---|
US (2) | US9643970B2 (es) |
EP (2) | EP3121178B1 (es) |
JP (1) | JP2015531401A (es) |
CN (2) | CN106905324B (es) |
AU (2) | AU2012323085B2 (es) |
BR (1) | BR112015007731B1 (es) |
CA (1) | CA2886885C (es) |
HK (1) | HK1211023A1 (es) |
IL (2) | IL237836A (es) |
IN (1) | IN2015DN02829A (es) |
MA (1) | MA37958B1 (es) |
MX (1) | MX370433B (es) |
SG (1) | SG11201502728WA (es) |
TN (1) | TN2015000100A1 (es) |
WO (1) | WO2013053690A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3121178B1 (en) * | 2011-10-10 | 2018-09-19 | H. Lundbeck A/S | 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
SG10201806849WA (en) | 2014-02-13 | 2018-09-27 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
CN107660205B (zh) | 2015-04-03 | 2021-08-27 | 因赛特公司 | 作为lsd1抑制剂的杂环化合物 |
JO3627B1 (ar) * | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
CN107810187B (zh) | 2015-07-07 | 2020-09-15 | H.隆德贝克有限公司 | 用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂 |
TW201717948A (zh) * | 2015-08-10 | 2017-06-01 | H 朗德貝克公司 | 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療 |
CR20180152A (es) | 2015-08-12 | 2018-08-09 | Incyte Corp | Sales de un inhibidor de lsd1 |
PT3374359T (pt) * | 2015-11-09 | 2020-03-27 | Astrazeneca Ab | Derivados de di-hidroimidazopirazinona úteis no tratamento do cancro |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
CA3021678A1 (en) | 2016-04-22 | 2017-10-26 | Incyte Corporation | Formulations of an lsd1 inhibitor |
EP3481398A1 (en) | 2016-07-06 | 2019-05-15 | Imara, Inc. | Pde9 inhibitors for treatment of peripheral diseases |
ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
CA3041607A1 (en) * | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
MX2019004859A (es) * | 2016-10-28 | 2019-06-20 | H Lundbeck As | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. |
US20200157092A1 (en) * | 2017-02-27 | 2020-05-21 | Janssen Pharmaceutlca NV | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
HRP20240146T1 (hr) * | 2017-05-26 | 2024-04-12 | Cardurion Pharmaceuticals, Inc. | Postupci dobivanja i upotrebe inhibitora pde9 |
TW201902898A (zh) | 2017-06-08 | 2019-01-16 | 美商默沙東藥廠 | 吡唑并嘧啶pde9抑制劑 |
WO2019101511A1 (en) | 2017-11-23 | 2019-05-31 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
CN117843645A (zh) * | 2018-05-25 | 2024-04-09 | 伊马拉公司 | 一种pde9抑制剂的一水合物和结晶形态 |
JP2021527662A (ja) * | 2018-06-20 | 2021-10-14 | ヤンセン ファーマシューティカ エヌ.ベー. | Oga阻害化合物 |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
CA3136128A1 (en) * | 2019-04-05 | 2020-10-08 | Imara Inc. | Pde9 inhibitors for treating sickle cell disease |
WO2020227399A1 (en) * | 2019-05-07 | 2020-11-12 | Imara Inc. | Pde9 inhibitors for treating thalassemia |
WO2022036111A1 (en) * | 2020-08-13 | 2022-02-17 | Imara Inc. | Methods and compositions for treating sickle cell disease |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59803108D1 (de) | 1997-11-12 | 2002-03-21 | Bayer Ag | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren |
SK10322001A3 (sk) | 1999-01-20 | 2002-07-02 | Arzneimittelwerk Dresden Gmbh | Spôsob prípravy imidazo [1,5-a]pyrido[3,2-e]pyrazínov, farmaceutické prostriedky obsahujúce takéto zlúčeniny a spôsob výroby farmaceutického prostriedku |
HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Pde9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
GB2388111A (en) | 2002-05-01 | 2003-11-05 | Bayer Ag | Novel imidazotriazinone compounds |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
BRPI0416118A (pt) | 2003-10-31 | 2007-01-02 | Pfizer Prod Inc | inibição da fosfodiesterase 9 como tratamento para estados relacionados com a obesidade |
JP2009507032A (ja) | 2005-09-02 | 2009-02-19 | アボット・ラボラトリーズ | 新規なイミダゾ系複素環 |
TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
WO2008029589A1 (fr) | 2006-09-08 | 2008-03-13 | Tokuyama Corporation | Procédé et matériel servant à produire un nitrure d'un élément du groupe iii |
WO2008072778A1 (ja) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | 尿路系疾患の処置剤 |
US8299080B2 (en) | 2006-12-13 | 2012-10-30 | Aska Pharmaceutical Co., Ltd. | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor |
GEP20125405B (en) | 2007-05-11 | 2012-02-27 | Pfizer | Amino-heterocyclic compounds |
DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
US9260432B2 (en) | 2009-09-02 | 2016-02-16 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
EP3181566A1 (en) * | 2010-09-20 | 2017-06-21 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
RU2605096C2 (ru) | 2011-10-07 | 2016-12-20 | ЭЙСАЙ АрЭНДДи МЕНЕДЖМЕНТ КО., ЛТД. | Пиразолохинолиновое производное |
EP3121178B1 (en) * | 2011-10-10 | 2018-09-19 | H. Lundbeck A/S | 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor |
WO2013110768A1 (en) | 2012-01-26 | 2013-08-01 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone |
WO2013142269A1 (en) | 2012-03-19 | 2013-09-26 | Envivo Pharmaceuticals, Inc. | Imidazotriazinone compounds |
-
2012
- 2012-10-09 EP EP16185105.0A patent/EP3121178B1/en active Active
- 2012-10-09 CN CN201710247417.1A patent/CN106905324B/zh active Active
- 2012-10-09 MA MA37958A patent/MA37958B1/fr unknown
- 2012-10-09 JP JP2015535994A patent/JP2015531401A/ja active Pending
- 2012-10-09 US US14/434,308 patent/US9643970B2/en active Active
- 2012-10-09 MX MX2015004422A patent/MX370433B/es active IP Right Grant
- 2012-10-09 AU AU2012323085A patent/AU2012323085B2/en active Active
- 2012-10-09 CA CA2886885A patent/CA2886885C/en active Active
- 2012-10-09 CN CN201280076285.6A patent/CN104703987B/zh active Active
- 2012-10-09 EP EP12772769.1A patent/EP2906562B1/en active Active
- 2012-10-09 SG SG11201502728WA patent/SG11201502728WA/en unknown
- 2012-10-09 BR BR112015007731-5A patent/BR112015007731B1/pt active IP Right Grant
- 2012-10-09 WO PCT/EP2012/069936 patent/WO2013053690A1/en active Application Filing
- 2012-10-09 IN IN2829DEN2015 patent/IN2015DN02829A/en unknown
-
2015
- 2015-03-16 TN TNP2015000100A patent/TN2015000100A1/fr unknown
- 2015-03-19 IL IL237836A patent/IL237836A/en active IP Right Grant
- 2015-11-27 HK HK15111740.3A patent/HK1211023A1/xx unknown
-
2017
- 2017-03-08 US US15/452,827 patent/US9993477B2/en active Active
- 2017-03-20 AU AU2017201873A patent/AU2017201873C1/en active Active
- 2017-07-12 IL IL253448A patent/IL253448A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20170173018A1 (en) | 2017-06-22 |
EP2906562A1 (en) | 2015-08-19 |
AU2017201873C1 (en) | 2018-08-02 |
IL253448A0 (en) | 2017-09-28 |
MX2015004422A (es) | 2015-10-15 |
EP3121178A1 (en) | 2017-01-25 |
CN104703987B (zh) | 2017-05-03 |
AU2012323085B2 (en) | 2017-03-09 |
MA37958A1 (fr) | 2017-11-30 |
MA37958B1 (fr) | 2018-10-31 |
IL237836A (en) | 2017-07-31 |
AU2017201873A1 (en) | 2017-04-06 |
AU2012323085A1 (en) | 2015-04-02 |
CA2886885A1 (en) | 2013-04-18 |
US20150274736A1 (en) | 2015-10-01 |
BR112015007731B1 (pt) | 2022-05-31 |
IN2015DN02829A (es) | 2015-09-11 |
EP2906562B1 (en) | 2016-10-05 |
CA2886885C (en) | 2019-07-16 |
JP2015531401A (ja) | 2015-11-02 |
CN106905324A (zh) | 2017-06-30 |
CN104703987A (zh) | 2015-06-10 |
TN2015000100A1 (en) | 2016-06-29 |
US9993477B2 (en) | 2018-06-12 |
SG11201502728WA (en) | 2015-05-28 |
HK1211023A1 (en) | 2016-05-13 |
CN106905324B (zh) | 2018-09-25 |
AU2017201873B2 (en) | 2018-03-29 |
WO2013053690A1 (en) | 2013-04-18 |
EP3121178B1 (en) | 2018-09-19 |
US9643970B2 (en) | 2017-05-09 |
BR112015007731A2 (pt) | 2017-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2015000100A1 (en) | Pde9i with imidazo pyrazinone backbone | |
PH12014501695B1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
MY152949A (en) | Novel phenylimidazole derivatives as pde10a enzyme inhibitors | |
TN2012000287A1 (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
JO3089B1 (ar) | مشتقات ايميدازول كمثبطات لانزيمات pde10a | |
UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a | |
TN2012000271A1 (en) | Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors | |
MY156520A (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors | |
MD20140070A2 (ro) | Derivaţi de chinolină ca inhibitori ai enzimei PDE10A | |
TN2014000288A1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
MX336915B (es) | Derivados de imidazol como inhibidores de la enzima pde10a. | |
TN2013000200A1 (en) | Imidazole derivatives as pde 10a enzyme inhibitors | |
MX2019014982A (es) | Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos. | |
CY1116689T1 (el) | Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |